Melanoma tumors use interferon-gamma mutations to fight immunotherapy

Melanoma tumors use genetic mutations in a prominent immune response pathway to resist the immunotherapy ipilimumab, researchers report. These findings open the door to testing an array of IFN-y genes prospectively as a predictor for response to ipilimumab and for exploring new combinations to defeat IFN-y-related resistance.

Read the whole article on Science Daily

More from Science Daily